Kestra Medical Technologies Ltd Dossier - Source-backed chat

Kestra Medical Technologies Ltd

KMTSNASDAQ

SectorHealth Care

IndustryMedical Instruments & Supplies

Beta (adjusted)0.73

Intrinsic Value $29.79median of 2 methodsbased on filings through 31 Jul 2026

Market Price $27.11Price as of 1 Oct 2026

Near fair valueIntrinsic value is 10% above the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $1.6B

Enterprise Value $1.6B

Shares Outstanding 61.4M diluted

Next Earnings Date14 Dec 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Kestra Medical Technologies (NASDAQ: KMTS) is a rapidly growing, commercial-stage medtech company disrupting the wearable cardioverter defibrillator (WCD) market with its flagship ASSURE® system. Historically a monopoly dominated by Zoll Medical's LifeVest, Kestra is successfully capturing market share by offering a highly differentiated, patient-centric design that dramatically improves comfort and compliance while reducing false-positive shock alarms. Backed by strong clinical data from the ACE-PAS and ACE-DETECT trials, Kestra is experiencing rapid commercial adoption, with revenue growing over 50% year-over-year and gross margins expanding past the 50% milestone. With a massive underpenetrated market where only 14% of eligible patients currently receive a WCD, Kestra has a long runway for high-margin growth.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets7 analysts · as of 18 Aug 2026

Low · most bearish analyst$28.00

Mean target$30.00

High · most bullish analyst$32.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

Zoll Medical aggressively defends its market share through pricing pressure or exclusive hospital contracts, stalling Kestra's sales momentum. High operating expenses and cash burn persist, requiring dilutive equity financing. Regulatory or reimbursement changes negatively impact WCD coverage.

Base CaseCentral scenario

Kestra continues to execute on its commercial expansion, leveraging its expanded sales force to drive double-digit prescription growth. Gross margins continue to improve toward mid-50s driven by volume leverage and a higher mix of in-network patients. The company successfully integrates Biobeat's ambulatory blood pressure monitoring technology to expand its clinical value proposition.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Disrupting a historical monopoly (Zoll Medical) with a superior, patient-focused product design that improves wear-time compliance.
Strong clinical validation from the ACE-PAS and ACE-DETECT trials, showing a near-zero rate of missed events and a massive reduction in false-positive shock alarms.
Rapid revenue growth (exceeding 50% YoY) and significant gross margin expansion (surpassing 50% in Q2 FY26).
Robust balance sheet with approximately $175 million in cash as of late 2025, further bolstered by a $148 million net proceeds equity offering.

Key Investment Risks

High concentration risk as a single-product company dependent entirely on the ASSURE® WCD system.
Intense competition from a well-entrenched, dominant incumbent (Zoll Medical) with deep physician relationships and scale.
Significant ongoing operating losses as the company heavily invests in scaling its commercial organization and R&D.

Thesis Invalidation Triggers

A sharp deceleration in prescription growth or hospital activation rates.
A decline in gross margins below 45% due to pricing pressure or unfavorable payer mix.
Safety issues or product recalls related to the ASSURE® system.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.